Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
En utvärdering av 5-HT1A-receptoragonisten vilazodone för en utökad antidepressiv effekt i behandlingen av egentlig depression
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
2017 (Swedish)Independent thesis Basic level (degree of Bachelor), 10 credits / 15 HE creditsStudent thesisAlternative title
Evaluation of the antidepressant effect of vilazodone for the treatment of major depression (English)
Abstract [en]

Major depressive disorder (MDD) is a mood disorder majorly responsible for disability and mortality worldwide. With a lifetime prevalence of 15-20%, it is the main cause of functional impairment in Western societies as well as the fourth most debilitating illness in the world. Although the pathophysiology of MDD is not yet fully understood, some evidence that suggest the presence of a neuroanatomical deficiency have given rise to the theory of a specific imbalance in the monoamine neurotransmitters noradrenaline (NA) and/or serotonin (5-HT) levels in the brain. Overall, the various classes of antidepressant agents that have been developed to increase monoamine levels on the basis of this proposal have been successful. However, facts relating to prevalent escalation in the illness and recurring episodes of depression point towards a need to enhance clinical treatment. Most conventional antidepressants such as selective serotonin reuptake inhibitors (SSRI) and selective serotonin and noradrenaline inhibitors (SNRI) pose problems in symptomatic improvement. These include therapeutic lag, safety and tolerability issues, making more than 30% patients with MDD unable to reach adequate relief. In this respect, the action mechanism has moved beyond conventional SSRI and lead to the introduction of vilazodone, a novel antidepressant with an additional 5-HT1A partial agonist profile argued to be of potential benefit for a greater efficacy, faster onset of action and better tolerability. Using secondary data, this project aimed to evaluate the role of vilazodone as a SPARI-drug in the overall clinical treatment of MDD as well as its potential in addressing some of the most common obstacles in antidepressant treatment. Study results proved vilazodone’s efficacy to be superior to placebo. Patients across all studies showed significant improvement in depressive symptoms measured in MADRS and HAMD17. Vilazodone was also shown to be generally safe and tolerable but was not positively distinguished from placebo with regards to adverse effects. An overall, meaningful improvement in depressive symptoms was demonstrated in vilazodone, which reinforces its merit as an important treatment option for patients with MDD. 

Place, publisher, year, edition, pages
2017. , p. 29
Keywords [en]
vilazodone, viibryd, SPARI, 5-HT1A, 5-HT1A agonist, SSRI, SNRI, MDD, major depression, major depressive disorder, selective serotonin reuptake inhibitor, selective serotonin- and noradrenalin reuptake inhibitor, depression drug therapy
Keywords [sv]
vilazodone, viibryd, SPARI, 5-HT1A, 5-HT1A agonist, SSRI, SNRI, MDD, depression, egentlig depression, selektiva serotoninåterupptagshämmare, selektiva serotonin- och noradrenalinåterupptagshämmare
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:uu:diva-336781OAI: oai:DiVA.org:uu-336781DiVA, id: diva2:1167013
Subject / course
Pharmaceutical Biosciences
Educational program
Bachelor of Science Programme in Pharmacy
Supervisors
Examiners
Available from: 2017-12-18 Created: 2017-12-17 Last updated: 2018-01-13Bibliographically approved

Open Access in DiVA

fulltext(940 kB)30 downloads
File information
File name FULLTEXT01.pdfFile size 940 kBChecksum SHA-512
9c3c2f9f24c782456faa729137cfd5e4c585e5efc85dbbd0b11b291078fa18f05a96b9ece113ba8c4e5c57d9f2d260fb240229403fe0712ebcaeb1fbfe6fcfe3
Type fulltextMimetype application/pdf
populärvetenskaplig sammanfattning(83 kB)1 downloads
File information
File name POPULARSUMMARY01.pdfFile size 83 kBChecksum SHA-512
a53881d922ec6c863836a1f42c45f350782e2caad57cd3a430927a79761eeca5838b9fc5c29f748bc8f4e7d9602dd213ea691d6dbbe8e77019c7bd023d42556e
Type popularsummaryMimetype application/pdf

By organisation
Department of Pharmaceutical Biosciences
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 30 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 39 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf